TSS

52

2.6

50

1.7

0.9
[0.3, 1.6]

<0.001

Erosion

28

1.6

25

1.1

0.5
[0.1, 1.0]

0.024

JSN

24

1.1

25

0.7

0.4
[0.1, 0.7]

<0.001

^* Differences and 95% confidence intervals for the differences in change scores between Placebo/MX and Kineret^®/MTX

^** Based on Wilcoxon rank-sum test

The disability index of the Health Assessment Questionnaire (HAQ) was administered monthly for the first six months and quarterly thereafter during study 1. Health outcomes were assessed by the Short Form-36 (SF-36) questionnaire. The 1-year data on HAQ in study 1 showed more improvement with Kineret^® than placebo. The physical component summary (PCS) score of the SF-36 also showed more improvement with Kineret^® than placebo but not the mental component summary (MCS).